论文部分内容阅读
目的:研究马鞭草醇提液(EVO)联合紫杉醇(PTX)在体外和体内的抗肿瘤效果。方法:采用MTT法测定EVO与PTX单用以及联用对小鼠S180细胞的增殖抑制率;建立S180皮下种植瘤小鼠模型,观察EVO与PTX单用以及联用对小鼠皮下瘤的生长抑制作用。结果:体外实验发现在PTX的各个浓度下(3.75,7.50,15.00,30.00,60.00ng/ml),EVO20mg/ml联合后的细胞抑制效果均明显强于PTX单药。体内实验证实当EVO1g/kg与PTX10mg/kg联用时则对肿瘤生长产生了明显的抑制作用,与PTX10mg/kg单用相比具有显著性差异(P<0.05)。结论:体外和体内实验证实EVO在小剂量时能够显著增加PTX的抗肿瘤活性,这为提高临床常用化疗药物的疗效且减少增加剂量带来的不良反应提供了新的思路。
Objective: To study the anti-tumor effects of verbena extract (EVO) combined with paclitaxel (PTX) in vitro and in vivo. METHODS: MTT assay was used to determine the proliferation inhibition rate of mouse S180 cells treated with EVO and PTX alone or in combination. A mouse model of S180 subcutaneous tumors was established. The growth inhibition of mouse subcutaneous tumors with EVO and PTX alone and in combination was observed. effect. RESULTS: In vitro experiments showed that at various concentrations of PTX (3.75, 7.50, 15.00, 30.00, 60.00 ng/ml), the cell inhibitory effect of EVO 20 mg/ml was significantly stronger than that of PTX alone. In vivo experiments confirmed that when EVO1g/kg was combined with PTX10mg/kg, it had a significant inhibitory effect on tumor growth, and there was a significant difference compared with PTX10mg/kg alone (P<0.05). Conclusion: The in vitro and in vivo experiments confirmed that EVO can significantly increase the anti-tumor activity of PTX at low doses. This provides a new idea for improving the efficacy of commonly used chemotherapy drugs and reducing the adverse reactions caused by increasing doses.